$4.85
5.43% yesterday
Nasdaq, Dec 24, 09:26 pm CET
ISIN
US28658R1068
Symbol
CLYM

Eliem Therapeutics Inc Stock price

$4.85
+3.09 175.57% 1M
+3.56 275.97% 6M
+3.05 169.44% YTD
+2.87 144.95% 1Y
+1.92 65.53% 3Y
-11.05 69.50% 5Y
-11.05 69.50% 10Y
-11.05 69.50% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.25 5.43%
ISIN
US28658R1068
Symbol
CLYM
Industry

Key metrics

Basic
Market capitalization
$330.7m
Enterprise Value
$243.8m
Net debt
positive
Cash
$86.9m
Shares outstanding
68.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.9
Financial Health
Equity Ratio
97.6%
Return on Equity
-34.9%
ROCE
-31.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-56.1m | -
EBIT
$-56.1m | $-65.4m
Net Income
$-50.8m | $-57.0m
Free Cash Flow
$-44.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
-149.5% | -142.2%
Net Income
26.6% | 22.8%
Free Cash Flow
-184.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.8
FCF per Share
$-0.7
Short interest
5.1%
Employees
-
Rev per Employee
-
Show more

Is Eliem Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Eliem Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Eliem Therapeutics Inc forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Eliem Therapeutics Inc forecast:

Buy
92%
Hold
8%

Financial data from Eliem Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 20 20
53% 53%
-
- Research and Development Expense 36 36
281% 281%
-
-56 -56
-
-
- Depreciation and Amortization 0.07 0.07
-
-
EBIT (Operating Income) EBIT -56 -56
149% 149%
-
Net Profit -51 -51
27% 27%
-

In millions USD.

Don't miss a Thing! We will send you all news about Eliem Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Eliem Therapeutics Inc Stock News

Neutral
GlobeNewsWire
about one month ago
WELLESLEY HILLS, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that Climb Bio has granted an inducement equity award to a new employee, pursuant to the Climb Bio's 2025 Inducement Plan, as amended, as an inducement material to the new employee ent...
Neutral
GlobeNewsWire
about 2 months ago
PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated  Phase 1 trial of budoprutug subcutaneous formulation initiated, with initial data expected in H1 2026 Clinical trials of budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) ongoing, with initial data from both trials expected in H2 2026 Regulatory clearance obtained to initiate C...
Neutral
GlobeNewsWire
about 2 months ago
WELLESLEY HILLS, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its executive team will participate in the upcoming investor conferences detailed below.
More Eliem Therapeutics Inc News

Company Profile

Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its clinical-stage candidates are ETX-810 and ETX-155. ETX-810 is a novel palmitoylethanolamide (PEA) prodrug initially being developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy. ETX-155 is a neurosteroid GABAA receptor positive allosteric modulator (PAM) initially being developed for major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizures. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Redmond, WA.

Head office United States
CEO Aoife Brennan
Founded 2018
Website climbbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today